Roche Acquires Tusk Therapeutics for $81. 24 M (€70M) for Its Novel Antibody

 Roche Acquires Tusk Therapeutics for $81. 24 M (€70M) for Its Novel Antibody

Roche Acquires Tusk Therapeutics for $81. 24 M (€70M) for Its Novel Antibody

Shots:

  • Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones
  • Roche plans to continue the development of novel Ab developed by Tusk for depleting regulatory T-cells. The program is expected to hit the clinics by Q4’19 for cancer patients
  • Tusk’s Spinout Black Belt Therapeutics, will hold the development of a remaining portfolio of immune-oncology targets excluding novel Ab

Click here to read full press release/ article | Ref: Tusk Therapeutics | Image: Tusk Therapeutics

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post